Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Episodes
195 episodes
How Epicrispr is leveraging CRISPR without cutting DNA
This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr.Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s propri...
Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases
Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics.A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he fo...
Argobio: the venture model building Europe’s next biotech champions
Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in...
Multi-agent AI delivers reliable and scalable insights for single-cell omics
Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data.Our guest is Parashar Dhapola, co-founder and CEO of
Nionyx Bio's kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight
This week we welcome Magdalena Tyrpien, CEO, Co-Founder and President of Nionyx Bio, just days after the company took first place in the
HaemaLogiX - precision immunotherapy for multiple myeloma
Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX, an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma a...
How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, and Clarissa Koch, the company's Chief Scientific Officer.Leyden Labs is pioneering a revolutionary non-vaccine approach to comba...
How to optimize your biotech company for partnering, licensing, and business success
Today, we welcome Janita Good, a Partner at Fieldfisher with nearly two decades of experience advising top organizations in pharmaceuticals, biotechnology, and medical devices. ...
Reversing tumor immunosuppression with next-gen GPCR modulation
Today we’re joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the c...
Misinformation is a public health crisis - here's how to fix it
Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ve...
Accelerating rare disease cures with ASOs, gene editing, and AI
Today, we're joined by Professor Matthew Wood, a leading figure in neuroscience and RNA-based therapeutics. He is Professor of Neuroscience at the University of Oxford, Deputy Head of the Medical Sciences Division, and Director of both the MDUK...
Using AI to crack undruggable drug targets
As we mark the International Day of Women and Girls in Science, we welcome Avital Sharir-Ivry, Co-Founder and Chief Scientific Officer of ProPhet, an innovative Israeli startup launched in late 2024 from the ...
How Eli Lilly's biotech collaboration model is rewriting early-stage innovation
Today, we're joined by Thomas Hopkins, Vice President and Head of ExploR&D at Eli Lilly. With a background as a physician-scientist in oncology, Thomas has spent his career bridging bold discovery science with rigorous development, first in...
Building a smart oncology pipeline with Cumulus Oncology
Today, my guest is Dr. Clare Wareing, Founder and CEO of Cumulus Oncology, who joins us from Edinburgh. With over 25 years of expertise in oncology drug development, Clare has built a r...
Top 5 trends that will drive biopharma in the next decade with Tim Opler
Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. Tim's career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acq...
Labiotech's 15 biopharma companies to watch in 2026
Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech player...
M Ventures: pharma CVC and biotech innovation in 2026
Welcome to our first episode for 2026.Today, we're joined by Hakan Goker, Managing Director at M Ventures, the strategic corporate venture capital arm of Merck KGaA. With over two decades in biote...
Johnson & Johnson’s hematology portfolio: breakthroughs to watch
Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker.Today, though, I...
Tackling pulmonary fibrosis: Boehringer Ingelheim’s new drug + AI approach
In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. Martin grew up just down the road from the company’s h...
Cracking Cancer’s Code: Transforming Research with Novel Cancer Models
Cancer is one of the biggest health challenges worldwide. While progress has been made, millions of patients are still in need of new treatment options that better address the complexities of their disease.BeOne Medicines is creating the...
Curing cancer: Daiichi Sankyo's ambitious ADC approach
Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients.In today’s episode I’m joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at D...
How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes
Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner a...
Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology
Last week saw more than 5,900 people from 3,200 companies gather in Vienna, Austria, for the continent’s largest biopharma partnering conference, BIO-Europe. Over three days the world’s top ph...
Next‑generation UTI diagnostics: delivering results in just 35 minutes
Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary t...
How AI Is revolutionizing synthetic biology and biomanufacturing
Today, I’m joined by Héctor García Martín, a Staff Scientist at Lawrence Berkeley National Laboratory. A pioneer in metabolic engineering and computational biology, Héctor has spent over a decade decoding microbial systems, everything from term...